Neuron23 Email Format
Biotechnology ResearchCalifornia, United States11-50 Employees
Neuron23 operates in the biotechnology sector with a focus on developing targeted therapies for Parkinson’s disease linked to hyperactive LRRK2. The company integrates human genetics with a drug discovery and biomarker platform to identify and advance treatments, and it applies machine learning and AI to support approaches that may influence disease progression. Headquartered in South San Francisco, California, the organization was founded in 2018 and employs a mid-sized team. A recent development involves expanding its NEULARK Phase II trial into Israel, adding clinical sites across Tel Aviv, Jerusalem, and Haifa.